Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Divi's Laboratories Limited engages in the manufacture and sale of generic active pharmaceutical ingredients (APIs), intermediates, and nutraceuticals in India, North America, Asia, Europe, and internationally. The company also undertakes custom synthesis contract manufacturing services of APIs and intermediates; and supplies a range of carotenoids, such as beta carotene, astaxanthin, lycopene, and canthaxanthin, as well as other finished forms, including lutein, and vitamins to food, dietary supplement, and feed manufacturers industries. It also exports its products. The company was formerly known as Divi's Research Center and changed its name to Divi's Laboratories Limited in 1994. Divi's Laboratories Limited was incorporated in 1990 and is based in Hyderabad, India.

Revenue projections:

Revenue projections for DIVISLAB
Revenue projections for DIVISLAB

Revenues for DIVISLAB are forecasted to decline from last year's levels, prompting caution among investors. When revenues fall, it can have a significant negative impact on the company's bottom line, reducing profitability and making the stock less attractive to risk-averse investors.

Financial Ratios:

currentRatio 5.43100
forwardPE 47.54237
debtToEquity 0.04200
earningsGrowth 0.13600
revenueGrowth 0.09500
grossMargins 0.61241
operatingMargins 0.28753
trailingEps 96.67000
forwardEps 140.92693

Divi's Laboratories Limited's current ratio of 5.431 reflects its strong liquidity position. The company has enough cash reserves and current assets to service its short-term debt obligations, signaling that Divi's Laboratories Limited is financially well-prepared to meet its liabilities without difficulty.
DIVISLAB's positive gross and operating margins reflect strong financial performance. These metrics indicate that the company is efficiently managing its operations and generating healthy profits, contributing to a solid financial position.
With a forward EPS greater than its trailing EPS, Divi's Laboratories Limited is forecasted to be more profitable this year than last. This growth expectation reflects confidence in the company's earnings potential and suggests an improving financial trajectory for the year ahead.

Price projections:

Price projections for DIVISLAB
Price projections for DIVISLAB

DIVISLAB's price has consistently hovered around the lower end of analysts' projections. This pattern may reflect concerns regarding the company's ability to achieve its anticipated growth.

Insider Transactions:

Insider Transactions for DIVISLAB
Insider Transactions for DIVISLAB


There were 7 DIVISLAB sales transactions, at market price of 6672.571428571428.1 transactions to buy DIVISLAB shares were recorded, with market price at 6553.5.Increased sells at DIVISLAB's current price levels point to a possible decline. If this trend of selling continues, it may signal that the stock's price will face further downward pressure, reflecting investor concerns.

Recommendation changes over time:

Recommendations trend for DIVISLAB
Recommendations trend for DIVISLAB


Analysts have shown a buy bias for DIVISLAB, marking it as a favorable investment option. This could inspire investors to see DIVISLAB as a strong place to park their money, given the positive outlook and growth potential associated with the stock in recent evaluations.